Unresectable Breast Cancer (DBCOND0121828)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Tucatinib	A kinase inhibitor used to treat certain types of unresectable/metastatic HER-2 positive breast cancer.	Receptor tyrosine-protein kinase erbB-2target Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-dependent translocase ABCB1transporter Solute carrier family 22 member 2transporter Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter Cytochrome P450 2C8enzyme Cytochrome P450 3A Subfamilyenzyme Receptor tyrosine-protein kinase erbB-2enzyme Receptor tyrosine-protein kinase erbB-3target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05977036	BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer	No drug interventions	treatment	Not Available	recruiting
NCT06386263	HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada	Trastuzumab deruxtecan	Not Available	Not Available	recruiting
NCT04042051	Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer	Copanlisib Trastuzumab emtansine	treatment	1	terminated
NCT04872608	A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer	Letrozole Onapristone Palbociclib	treatment	1	withdrawn
NCT05945732	DESTINY Breast Respond HER2-low Europe	Trastuzumab deruxtecan	Not Available	Not Available	recruiting